JNJ reports Remicade psoriasis data

In a double-blind, placebo-controlled Phase II study of 33 psoriasis patients, 5 and 10 mg/kg of Johnson & Johnson's Remicade infliximab anti-TNF chimeric monoclonal antibody gave 82 and 91 percent re...